Science
Five domains. Same direction of effect.
We measured the layer before we named it. Across five high-stakes professional work products, deployment-time fidelity treatment drives measured fabricated propositions toward the floor — and output quality rises rather than falls.
The evidence board
Fabricated propositions, before and after treatment.
| Domain | Baseline | After fidelity layer | Independent check |
|---|---|---|---|
| Private-equity IC memos | ~15% | 0.3% | Numeric reconciliation vs. source packet |
| Legal IRAC memos | 31–61%* | 0.2–3.5% | Legal-research oracle verified quotes |
| Medical evidence synthesis | ~17% | 0.7% | ClinicalTrials.gov / NCBI registries |
| Cyber vulnerability advisories | ~12% | 0.3% | NVD / CISA KEV — zero phantom CVEs |
| Patent prior-art analysis | ~7% | 0.2% | USPTO records — zero phantom patents |
*Baseline rates are judge-dependent. The treated floor is the robust claim. Figures are research findings for public orientation, not product guarantees; protocols and per-arm boards are shared in qualified review contexts.
Research briefing
For serious technical and strategic readers.
Deeper methodology and evidence — protocols, per-arm boards, and the cross-judge normalization work — are shared in qualified strategic, enterprise, or research contexts.
Request research briefing